Get the Stockscreener App
1.80
7.69%
-0.15
MAIA Biotechnology Inc stock is traded at $1.80, with a volume of 315.26K.
It is down -7.69% in the last 24 hours and down -12.62% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.95
Open:
$2.01
24h Volume:
315.26K
Relative Volume:
1.37
Market Cap:
$55.08M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.3043
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+0.56%
1M Performance:
-12.62%
6M Performance:
-13.46%
1Y Performance:
-45.78%
1-Day Range:
$1.7601
$2.04
1-Week Range:
$1.71
$2.05
52-Week Range:
$1.40
$4.3099
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.80 | 55.08M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Reports Positive Phase 2 Trial Results - TipRanks
Why Is MAIA Biotechnology Stock Trading Higher On Thursday?MAIA Biotechnology (AMEX:MAIA) - Benzinga
MAIA Biotechnology's Promising Results in Lung Cancer Trial | MA - GuruFocus
MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial - marketscreener.com
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial - Business Wire
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Reports Promising Results from THIO-101 Phase 2 Trial | MAIA Stock News - GuruFocus
Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study - marketscreener.com
Maia Biotechnology stock rises following positive trial results By Investing.com - Investing.com Canada
Maia Biotechnology stock rises following positive trial results - Investing.com Australia
MAIA Biotechnology Showcases Promising THIO-101 Trial Data - TipRanks
MAIA Biotechnology Announces Private Placement Agreement - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 4.1% Higher – Still a Buy? - Defense World
MAIA Biotechnology secures $669,500 in private placement By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Private Placement of Approximately $669,500 - BioSpace
MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial - Yahoo
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 - BioSpace
MAIA Biotechnology secures $669,500 in private placement - Investing.com
MAIA Biotechnology doubles authorized shares - Investing.com Australia
MAIA Biotechnology doubles authorized shares By Investing.com - Investing.com South Africa
MAIA Biotechnology Increases Authorized Common Stock Shares - TipRanks
MAIA Biotechnology Approves Key Changes at Annual Meeting - TipRanks
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks
MAIA Biotechnology launches $1.08M private placement - MSN
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada
Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com
MAIA Biotechnology secures $1.08 million in private placement - Investing.com
MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan
MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan
MAIA Biotechnology Inc (MAIA) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Do investors need to be concerned about MAIA Biotechnology Inc (MAIA)? - uspostnews.com
MAIA Biotechnology Inc: Navigating Market Fluctuations with a 60.66M Market Cap - investchronicle.com
MAIA Biotechnology Inc [MAIA] stock for 50,000 USD was acquired by Guerrero Ramiro - knoxdaily.com
MAIA’s Q2 earnings predictions: What the experts say - uspostnews.com
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 14.8% – Here’s Why - Defense World
MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN
MAIA stock touches 52-week low at $1.41 amid market challenges - Investing.com India
MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener
MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com
Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Business Wire
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Cap:
|
Volume (24h):